

COMMISSIONER FOR PATENT UNITED STATES PATENT AND TRADEMARK OFFIC P.O. BOX 1 450 ALEXANDRIA, VA 22313-1450 WWW.USDD.OD

AUG 11 2003

#21

David T. Read Acting Director Health Assessment Policy Staff, CDER Food and Drug Administration 1451 Rockville Pike, HFD-7 Rockville, MD 20852

Dear Mr. Read:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,688,819. The application was filed on May 11, 2001, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).

Karin Ferriter

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

CC:

Mr. Robert J. Baran Allergan, Inc. 2525 Dupont Drive Irvine CA 92612

RE: LUMIGAN® Docket No. 03E-0037